SGLT2 inhibitors do not reduce 28-day mortality in hospitalized COVID-19 patients

Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Opinion | How Should I Prioritize Self-Care During Training?

Welcome to “Ask the Program Director,” a column from MedPage Today where your most pressing questions about residency — from the application process to life

January 15, 2025

Long-term grape consumption shown to improve muscle health in both men and women

A new study from Western New England University (WNE) has revealed that long-term grape consumption significantly impacts muscle health, with notable benefits for both men

February 20, 2025

Skip Surgery for DCIS in Favor of Active Monitoring?

SAN ANTONIO — Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended

December 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.